Viracta Therapeutics (VIRX) Short Interest Ratio & Short Volume $0.0098 0.00 (0.00%) As of 07/24/2025 Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Viracta Therapeutics Short Interest DataViracta Therapeutics (VIRX) has a short interest of 8,100 shares, representing 0.02% of the float (the number of shares available for trading by the public). This marks a -41.73% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 1.11 million shares to cover all short positions.Current Short Interest8,100 sharesPrevious Short Interest13,900 sharesChange Vs. Previous Month-41.73%Dollar Volume Sold Short$134.46Short Interest Ratio0.0 Days to CoverLast Record DateJune 30, 2025Outstanding Shares39,744,000 sharesShort Percent of Float0.02%Today's Trading Volume0 sharesAverage Trading Volume1,111,440 sharesToday's Volume Vs. Average0% Short Selling Viracta Therapeutics? Sign up to receive the latest short interest report for Viracta Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVIRX Short Interest Over TimeVIRX Days to Cover Over TimeVIRX Percentage of Float Shorted Over Time Viracta Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/20258,100 shares $134.46 -41.7%0.0%0 $0.02 6/15/202513,900 shares $243.25 -38.5%0.0%0.1 $0.02 5/31/202522,600 shares $413.58 -23.1%0.1%0.1 $0.02 5/15/202529,400 shares $514.50 -26.3%N/A0.2 $0.02 4/30/202539,900 shares $833.91 +405.1%N/A0.3 $0.02 4/15/20257,900 shares $132.72 -21.0%N/A0 $0.02 3/14/202528,200 shares $733.20 +108.9%N/A0 $0.03 2/14/202523,200 shares $396.72 -87.4%N/A0 $0.02 1/31/2025184,200 shares $27.91 thousand -25.1%0.7%0.1 $0.15 1/15/2025246,000 shares $40.34 thousand -59.7%0.9%0.1 $0.16 Get the Latest News and Ratings for VIRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/2024609,900 shares $98.13 thousand -79.7%2.2%0.2 $0.16 12/15/20243,000,000 shares $608.10 thousand +89.9%10.7%1.4 $0.20 11/30/20241,580,000 shares $221.20 thousand -24.8%5.7%0.8 $0.14 11/15/20242,100,000 shares $317.10 thousand -21.9%7.5%2 $0.15 10/31/20242,690,000 shares $542.84 thousand +144.6%9.7%1.9 $0.20 10/15/20241,100,000 shares $241.56 thousand -17.3%4.0%1.7 $0.22 9/30/20241,330,000 shares $307.76 thousand +1.5%4.8%2.1 $0.23 9/15/20241,310,000 shares $328.81 thousand +4.0%4.7%2.1 $0.25 8/31/20241,260,000 shares $269.14 thousand -50.4%4.6%2.1 $0.21 8/15/20242,540,000 shares $885.19 thousand +178.5%9.2%4.8 $0.35 7/31/2024912,000 shares $436.85 thousand -6.4%3.3%8.5 $0.48 7/15/2024974,800 shares $517.62 thousand +35.2%3.5%10.7 $0.53 6/30/2024721,000 shares $392.01 thousand +1.7%2.6%7 $0.54 6/15/2024708,900 shares $477.66 thousand +3.8%2.6%6.7 $0.67 5/31/2024682,700 shares $477.89 thousand +2.1%2.5%6.3 $0.70 5/15/2024668,400 shares $561.46 thousand -4.4%2.4%6.5 $0.84 4/30/2024699,400 shares $573.23 thousand +1.9%2.5%6.3 $0.82 4/15/2024686,700 shares $535.63 thousand +6.0%2.5%6.2 $0.78 3/31/2024648,000 shares $660.96 thousand +2.2%2.4%6.8 $1.02 3/15/2024634,300 shares $631.76 thousand -7.1%2.3%5.7 $1.00 2/29/2024683,000 shares $556.65 thousand +0.6%2.5%5 $0.82 2/15/2024678,800 shares $433.75 thousand +4.5%2.5%4.5 $0.64 1/31/2024649,900 shares $370.44 thousand +0.4%2.4%4 $0.57 1/15/2024647,500 shares $384.23 thousand -1.9%2.4%3.8 $0.59 12/31/2023660,300 shares $376.37 thousand -14.9%2.5%3.8 $0.57 12/15/2023776,100 shares $361.97 thousand +19.3%2.9%4.6 $0.47 11/30/2023650,700 shares $316.89 thousand -8.2%2.4%4.9 $0.49 11/15/2023708,700 shares $425.50 thousand +3.0%2.6%7.3 $0.60 10/31/2023688,200 shares $424.28 thousand +12.0%2.6%7.5 $0.62 10/15/2023614,700 shares $436.44 thousand -2.7%2.3%7.6 $0.71Is this the biggest winner of Trump’s tariffs? (Ad)America’s industrial comeback is underway — and it’s bigger than anyone expected. Over $5 trillion has already been pledged to restore U.S. manufacturing. Trump’s tariffs and trade pressure have set off a massive reshoring push, and the flood of investment is still gaining steam. But while everyone’s watching the big names, one under-the-radar company holds the key tech that could make it all work — and potentially benefit the most.This could be the #1 America First stock of the decade. 9/30/2023632,000 shares $657.28 thousand -4.3%2.4%7 $1.04 9/15/2023660,200 shares $838.45 thousand -5.3%2.5%7.8 $1.27 8/31/2023697,200 shares $1.00 million -4.4%2.6%6.8 $1.44 8/15/2023729,100 shares $947.83 thousand +5.2%2.7%4.5 $1.30 7/31/2023692,900 shares $1.07 million -3.9%2.6%2.8 $1.55 7/15/2023721,000 shares $1.05 million -1.0%2.7%2.9 $1.45 6/30/2023728,500 shares $1.03 million -7.8%2.8%3 $1.41 6/15/2023789,900 shares $1.26 million +14.0%3.0%3.3 $1.59 5/31/2023693,200 shares $921.96 thousand +12.4%2.6%3.2 $1.33 5/15/2023616,700 shares $807.88 thousand -2.2%2.3%3.4 $1.31 4/30/2023630,800 shares $813.73 thousand +2.0%2.4%8.4 $1.29 4/15/2023618,300 shares $902.72 thousand -2.5%2.3%9.6 $1.46 3/31/2023634,000 shares $1.01 million -19.5%2.4%8.4 $1.59 3/15/2023787,800 shares $1.33 million +51.7%3.0%8.7 $1.69 2/28/2023519,200 shares $882.64 thousand +3.9%2.0%4.9 $1.70 2/15/2023499,500 shares $994.01 thousand +5.6%1.9%4.5 $1.99 1/31/2023473,000 shares $983.84 thousand -2.5%1.8%3.8 $2.08 1/15/2023485,300 shares $1.10 million +3.2%1.8%3.9 $2.26 12/30/2022470,300 shares $686.64 thousand -15.1%1.8%3.8 $1.46 12/15/2022553,600 shares $1.06 million -0.1%2.1%5.2 $1.92 11/30/2022553,900 shares $1.29 million +7.3%2.1%5.1 $2.32 11/15/2022516,200 shares $1.50 million +8.8%2.0%4.8 $2.90 10/31/2022474,600 shares $1.87 million -9.6%1.9%4.7 $3.93 10/15/2022525,100 shares $1.97 million -4.4%2.0%5.1 $3.75 9/30/2022549,000 shares $2.34 million +9.3%2.1%5 $4.27 9/15/2022502,100 shares $2.81 million -3.9%2.0%2.6 $5.59 8/31/2022522,300 shares $2.12 million +0.6%2.0%2.3 $4.05 8/15/2022519,100 shares $2.29 million -8.2%2.0%2.2 $4.42 7/31/2022565,400 shares $1.88 million -16.1%1.9%2.2 $3.32 7/15/2022673,800 shares $2.99 million -32.5%2.3%2.5 $4.44 6/30/2022998,500 shares $3.87 million -48.5%3.4%3.2 $3.88 6/15/20221,940,000 shares $4.85 million -3.0%6.5%6.1 $2.50 5/31/20222,000,000 shares $4.24 million +8.7%6.7%8.1 $2.12 5/15/20221,840,000 shares $3.44 million -7.1%6.2%7.3 $1.87 4/30/20221,980,000 shares $5.05 million +16.5%6.7%6.2 $2.55 4/15/20221,700,000 shares $6.90 million +20.6%5.7%5.2 $4.06 3/31/20221,410,000 shares $6.71 million +20.5%4.8%4.7 $4.76 3/15/20221,170,000 shares $2.61 million +13.6%3.9%4.2 $2.23 2/28/20221,030,000 shares $2.81 million +7.8%3.5%3.5 $2.73 2/15/2022955,900 shares $2.98 million +26.0%3.2%3 $3.12 1/31/2022758,800 shares $2.03 million +5.5%2.7%2.9 $2.68 1/15/2022719,100 shares $2.28 million -15.4%2.5%3.3 $3.17 12/31/2021849,800 shares $3.10 million -2.7%3.0%3.7 $3.65 12/15/2021873,100 shares $3.12 million +30.4%3.1%4 $3.57 11/30/2021669,400 shares $3.09 million -24.3%2.4%3.8 $4.61 11/15/2021884,500 shares $4.93 million -15.0%3.1%5.5 $5.57 10/29/20211,040,000 shares $6.12 million -7.1%3.5%6.6 $5.88 10/15/20211,120,000 shares $7.25 million -1.8%3.8%7.5 $6.47 9/30/20211,140,000 shares $9.14 million -5.0%3.8%8.5 $8.02 9/15/20211,200,000 shares $10.08 million -9.1%4.0%5.5 $8.40Is this the biggest winner of Trump’s tariffs? (Ad)America’s industrial comeback is underway — and it’s bigger than anyone expected. Over $5 trillion has already been pledged to restore U.S. manufacturing. Trump’s tariffs and trade pressure have set off a massive reshoring push, and the flood of investment is still gaining steam. But while everyone’s watching the big names, one under-the-radar company holds the key tech that could make it all work — and potentially benefit the most.This could be the #1 America First stock of the decade. 8/31/20211,320,000 shares $12.17 million -15.9%4.4%4.9 $9.22 8/13/20211,570,000 shares $16.11 million No Change5.3%5.7 $10.26 VIRX Short Interest - Frequently Asked Questions What is Viracta Therapeutics' current short interest? Short interest is the volume of Viracta Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 30th, investors have sold 8,100 shares of VIRX short. 0.02% of Viracta Therapeutics' shares are currently sold short. Learn More on Viracta Therapeutics' current short interest. What is a good short interest percentage for Viracta Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.02% of Viracta Therapeutics' floating shares are currently sold short. Is Viracta Therapeutics' short interest increasing or decreasing? Viracta Therapeutics saw a drop in short interest in June. As of June 30th, there was short interest totaling 8,100 shares, a drop of 41.7% from the previous total of 13,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Viracta Therapeutics' short interest compare to its competitors? 0.02% of Viracta Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Viracta Therapeutics: Salarius Pharmaceuticals, Inc. (33.45%), Bio-Path Holdings, Inc. (0.10%), Avenue Therapeutics, Inc. (2.48%), Oragenics, Inc. (45.59%), Panbela Therapeutics, Inc. (0.00%), Evofem Biosciences, Inc. (0.03%), Trevena, Inc. (0.38%), Petros Pharmaceuticals, Inc. (3.74%), Syros Pharmaceuticals, Inc. (0.51%), Sorrento Therapeutics, Inc. (0.67%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Viracta Therapeutics stock? Short selling VIRX is an investing strategy that aims to generate trading profit from Viracta Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Viracta Therapeutics? A short squeeze for Viracta Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VIRX, which in turn drives the price of the stock up even further. How often is Viracta Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VIRX, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies SLRX Short Squeeze BPTH Short Squeeze ATXI Short Squeeze OGEN Short Squeeze PBLA Short Squeeze EVFM Short Squeeze TRVN Short Squeeze PTPI Short Squeeze SYRS Short Squeeze SRNE Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VIRX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
